These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
697 related articles for article (PubMed ID: 30646277)
1. Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe. Khunti K; Danese MD; Kutikova L; Catterick D; Sorio-Vilela F; Gleeson M; Kondapally Seshasai SR; Brownrigg J; Ray KK JAMA Netw Open; 2018 Dec; 1(8):e185554. PubMed ID: 30646277 [TBL] [Abstract][Full Text] [Related]
2. Moderate-Intensity Statin With Ezetimibe Combination Therapy vs High-Intensity Statin Monotherapy in Patients at Very High Risk of Atherosclerotic Cardiovascular Disease: A Post Hoc Analysis From the RACING Randomized Clinical Trial. Lee SJ; Cha JJ; Choi WG; Lee WS; Jeong JO; Choi S; Cho YH; Park W; Yoon CH; Lee YJ; Hong SJ; Ahn CM; Kim BK; Ko YG; Choi D; Hong MK; Jang Y; Hong SJ; Kim JS; JAMA Cardiol; 2023 Sep; 8(9):853-858. PubMed ID: 37531130 [TBL] [Abstract][Full Text] [Related]
3. Differential Adherence to Free and Single-Pill Combination of Rosuvastatin/Ezetimibe: Findings from a Real-World Analysis in Italy. Perez de Isla L; Liberopoulos E; Dovizio M; Veronesi C; Degli Esposti L; Zambon A Adv Ther; 2024 Aug; 41(8):3407-3418. PubMed ID: 38963586 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the Efficacy of Ezetimibe Combination Therapy and High-Intensity Statin Monotherapy in Type 2 Diabetes. Park SY; Jun JE; Jeong IK; Ahn KJ; Chung HY; Hwang YC J Clin Endocrinol Metab; 2024 Jun; 109(7):1883-1890. PubMed ID: 38175670 [TBL] [Abstract][Full Text] [Related]
5. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial. Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276 [TBL] [Abstract][Full Text] [Related]
6. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335 [TBL] [Abstract][Full Text] [Related]
7. Patient characteristics, treatment patterns, and adherence to lipid-lowering therapies following an acute coronary syndrome. Bruckert E; Desamericq G; Khachatryan A; Ngo P; Gusto G; Sorio-Vilela F Rev Cardiovasc Med; 2020 Dec; 21(4):643-650. PubMed ID: 33388010 [TBL] [Abstract][Full Text] [Related]
8. Retrospective real-world analysis of adherence and persistence to lipid-lowering therapy in Germany. Koenig W; Lorenz ES; Beier L; Gouni-Berthold I Clin Res Cardiol; 2024 Jun; 113(6):812-821. PubMed ID: 37603070 [TBL] [Abstract][Full Text] [Related]
9. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes. Morieri ML; Perrone V; Veronesi C; Degli Esposti L; Andretta M; Plebani M; Fadini GP; Vigili de Kreutzenberg S; Avogaro A Cardiovasc Diabetol; 2021 Jul; 20(1):144. PubMed ID: 34271920 [TBL] [Abstract][Full Text] [Related]
10. Assessment of Trends in Statin Therapy for Secondary Prevention of Atherosclerotic Cardiovascular Disease in US Adults From 2007 to 2016. Yao X; Shah ND; Gersh BJ; Lopez-Jimenez F; Noseworthy PA JAMA Netw Open; 2020 Nov; 3(11):e2025505. PubMed ID: 33216139 [TBL] [Abstract][Full Text] [Related]
11. Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials. Lee M; Cheng CY; Wu YL; Lee JD; Hsu CY; Ovbiagele B JAMA Neurol; 2022 Apr; 79(4):349-358. PubMed ID: 35188949 [TBL] [Abstract][Full Text] [Related]
12. Association of Statin Adherence With Mortality in Patients With Atherosclerotic Cardiovascular Disease. Rodriguez F; Maron DJ; Knowles JW; Virani SS; Lin S; Heidenreich PA JAMA Cardiol; 2019 Mar; 4(3):206-213. PubMed ID: 30758506 [TBL] [Abstract][Full Text] [Related]
13. Association Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular Disease. Rodriguez F; Maron DJ; Knowles JW; Virani SS; Lin S; Heidenreich PA JAMA Cardiol; 2017 Jan; 2(1):47-54. PubMed ID: 27829091 [TBL] [Abstract][Full Text] [Related]
14. Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD). Shaik A; Kosiborod M; de Lemos JA; Gao Q; Mues KE; Alam S; Bhatt DL; Cannon CP; Ballantyne CM; Rosenson RS; Clin Cardiol; 2022 Dec; 45(12):1303-1310. PubMed ID: 36124341 [TBL] [Abstract][Full Text] [Related]
15. Combination of low- or moderate-intensity statin and ezetimibe vs. high-intensity statin monotherapy on primary prevention of cardiovascular disease and all-cause death: a propensity-matched nationwide cohort study. Jun JE; Jeong IK; Ahn KJ; Chung HY; Hwang YC Eur J Prev Cardiol; 2024 Aug; 31(10):1205-1213. PubMed ID: 38408362 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). Mihaylova B; Schlackow I; Herrington W; Lozano-Kühne J; Kent S; Emberson J; Reith C; Haynes R; Cass A; Craig J; Gray A; Collins R; Landray MJ; Baigent C; Am J Kidney Dis; 2016 Apr; 67(4):576-84. PubMed ID: 26597925 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Schlackow I; Kent S; Herrington W; Emberson J; Haynes R; Reith C; Collins R; Landray MJ; Gray A; Baigent C; Mihaylova B; Kidney Int; 2019 Jul; 96(1):170-179. PubMed ID: 31005271 [TBL] [Abstract][Full Text] [Related]
18. Cardiovascular event rates and trajectories of LDL-cholesterol levels and lipid-lowering therapy in patients with atherosclerotic cardiovascular disease: A population-based cohort study. Sundbøll J; Larsen AP; Veres K; Adelborg K; Sørensen HT Thromb Res; 2019 Nov; 183():124-130. PubMed ID: 31677592 [TBL] [Abstract][Full Text] [Related]
19. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines. Steen DL; Khan I; Ansell D; Sanchez RJ; Ray KK BMJ Open; 2017 Feb; 7(2):e013255. PubMed ID: 28213597 [TBL] [Abstract][Full Text] [Related]
20. Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis. Degli Esposti L; Saragoni S; Batacchi P; Benemei S; Geppetti P; Sturani A; Buda S; Degli Esposti E Clin Ther; 2012 Jan; 34(1):190-9. PubMed ID: 22284998 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]